Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327028 | 0.94 | GAA (0.64) | CA5AGAATSHRALDH1A1NFKB1 | |
| SCHEMBL1883666 | 0.92 | ALDH1A1 (0.58) | CA5AGAATSHRALDH1A1NFKB1 | |
| Bromide SCHEMBL10998875 | 0.90 | ALDH1A1 (0.57) | CA5AGAATSHRALDH1A1NFKB1 | |
| Hydrochloric Acid SCHEMBL2525777 | 0.90 | ALDH1A1 (0.57) | CA5AGAATSHRALDH1A1NFKB1 | |
| SCHEMBL153055 | 0.88 | GAA (0.74) | CA5AGAATSHRALDH1A1NFKB1 | |
| SCHEMBL30049382 | 0.88 | GAA (0.74) | CA5AGAATSHRALDH1A1NFKB1 | |
| SCHEMBL11435026 | 0.88 | CA5A (0.61) | CA5AGAATSHRALDH1A1NFKB1 | |
| SCHEMBL27952523 | 0.86 | GAA (0.72) | CA5AGAATSHRALDH1A1NFKB1 | |
| Hydrochloric Acid SCHEMBL2530820 | 0.86 | GAA (0.72) | CA5AGAATSHRALDH1A1NFKB1 | |
| SCHEMBL12327982 | 0.86 | CA5A (0.59) | CA5AGAATSHRALDH1A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-7709479-B1 | Quinazoline derivatives and their use as pharmaceuticals | ASTRAZENECA (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20100074861-A1 | COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-7074929-B2 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORP. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| EP-1529038-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| US-20040229870-A1 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2004016601-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2004-02-26 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001023389-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001023387-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0855387-A1 | 2-ACYLAMINOBENZAMIDE DERIVATIVES AND PREVENTIVE AND REMEDY FOR DISEASES CAUSED BY THE SUPERMULTIPLICATION OF VASCULAR INTIMAL CELLS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| US-5401604-A | Reaction product of polyepoxide, aromatic acid with phenolic hydroxy group, aromatic acid, quinone diazide with sulfonyl group, photoresists | NIPPON PAINT CO., LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-4493823-A | USING CARBOXYBENZENE COMPOUND | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-01-15 | — | — | US | disclosed |
| US-4247597-A | Electroscopic carrier particles having a carboxylic acid surface treatment | PITNEY BOWES, INC. (US) | 1981-01-27 | — | — | US | disclosed |
| EP-0017376-A1 | Phenylacetamide compounds and an analgesic composition containing them | KISSEI PHARMACEUTICAL CO. LTD (JP) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074861-A1 | COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | PAICS, ABCB4, ALPP | CA5A 300/4885GAA 615/4885TSHR 2981/4885 |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | CA5A 3198/4885GAA 3278/4885TSHR 360/4885 |
| US-20040229870-A1 | Certain alkylene diamine-substituted heterocycles | NPY1R, NPY5R, NPY2R | CA5A 686/4885GAA 3428/4885TSHR 167/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | CA5A 3198/4885GAA 3278/4885TSHR 360/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | CA5A 952/4885GAA 2255/4885TSHR 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.